In the study, ddPCR detected PD-L1 mRNAs with a dynamic range of 32–138 copies from plasma. If validated, such a test could offer additional information to physicians.
Promising initial findings demonstrate the technical feasibility of the PD-L1 circulating blood test.
Dr. Skibo discusses how ddPCR-based liquid biopsy could become an indispensable method for doctors to categorize a patient’s disease.
Dr. Paul Walker describes how liquid biopsy testing helps battling lung cancer in the tobacco belt. The advantages of liquid biopsy for lung cancer.